Lexaria FY26 nine-month net loss narrows to US$ 5.04 million; revenue drops to US$ 20,000

LEXX•2026-07-13

Lexaria posted a net loss of US$ 5.04 million for the nine months ended May 31, 2026, narrowing from US$ 9.21 million a year earlier.
Revenue fell to US$ 20,000 from US$ 531,923, reflecting the expiration of the Premier Anti-Aging licensing contract.
Research and development expense dropped to US$ 2.12 million from US$ 6.36 million after completing its Phase 1b GLP-1-H24-4 clinical trial in December 2025.
Cash used in operating activities improved to US$ 4.78 million from US$ 7.81 million, while cash and cash equivalents totaled about US$ 3.5 million.
Lexaria expects cash resources to fund operations through the first quarter of fiscal 2027, while flagging substantial doubt about its ability to continue as a going concern.

Sources

Sec